Non-blocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive anti-tumor responses and eliminates primary and metastatic tumors

Shengjun Lu, Jinyu Zhang, Dai Liu, Guangfu Li, Kevin F Staveley-O'Carroll, Zihai Li, and Jennifer Wu

1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425
2Department of Surgery, Medical University of South Carolina, Charleston, SC 29425
3Cancer Immunology Program, Hollings Cancer Center
4Department of Medicine, University of Washington, Seattle, WA 8910

Running Title: Targeting soluble MIC for Cancer Immunotherapy

Key Words: soluble MIC, Cancer Immunotherapy, neutralizing antibody

Correspondence should be addressed to:

Jennifer Wu, PhD
Department of Microbiology and Immunology
Medical University of South Carolina
86 Jonathan Lucas St., Hollings Cancer Center 610
Charleston, SC 29425
Email: wujjd@musc.edu
Tel: (843) 792-9222
Fax: (843) 792-9588
**Translational Relevance**

The human tumor-derived soluble MHC I-chain related molecule (sMIC) is highly immune suppressive in cancer patients and correlates with poor prognosis. However, whether sMIC is targetable for cancer therapy remains untested to date due to the lack of relevant preclinical models. Using an engineered MIC-expressing bi-transgenic mouse spontaneous tumor model that closely recapitulates the onco-immune dynamics of human cancer, we demonstrate that therapy with a sMIC-neutralizing non-blocking anti-MIC monoclonal can effectuate remarkable anti-tumor responses to induce regression of primary tumors and eliminate metastasis. Our findings provide the first-in-field evidence conveying the therapeutic power of neutralizing sMIC and build the rationale to translate the therapy into clinics.
Abstract

Purpose: The human tumor-derived soluble MHC I-chain related molecule (sMIC) is highly immune suppressive in cancer patients and correlates with poor prognosis. However, the therapeutic effect of targeting sMIC has not been determined, due to the limitation that mice do not express homologs of human MIC. This study is to evaluate the therapeutic effect of a monoclonal antibody targeting sMIC in a clinically relevant transgenic animal model.

Experimental Design: We treated the engineered MIC-expressing “humanized” TRAMP/MIC bi-transgenic mice at advanced disease stages with a sMIC-neutralizing non-blocking anti-MIC monoclonal antibody (mAb) and assessed the therapeutic efficacy and associated mechanisms.

Results: A sMIC-neutralizing non-blocking anti-MIC mAb effectively induced regression of primary tumors and eliminated metastasis without inducing systemic toxicity. The therapeutic effect is conferred by revamping endogenous anti-tumor immune responses, exemplified by restoring NK cell homeostasis and function, enhancing susceptibility of MIC⁺-tumor cells to NK cell killing, reviving and sustaining antigen-specific CD8 T cell responses, augmenting CD4 T cells to Th1 responses, priming dendritic cells for antigen presentation, and remodeling tumor microenvironment to be more immune reactive.

Conclusions: Therapy with a sMIC-neutralizing non-blocking anti-MIC mAb can effectuate anti-tumor immune responses against advanced MIC⁺ tumors. Our study provided strong rationale for translating sMIC-neutralizing therapeutic mAb into clinics, either alone or in combination with current ongoing standard immunotherapies.
Introduction

In response to oxidative stress and oncogenic insults, human epithelial cells were induced to express families of ligands for the immune stimulatory receptor NKG2D, presumably to provoke anti-tumor immune responses as a natural defense mechanism (1-4). In experimental animal models, ligand-induced activation of NKG2D has been demonstrated very effective in controlling tumor initiation and progression through activating NK and co-stimulating effector T cells, including cytotoxic T lymphocytes and NKT cells (5, 6). Notably, retaining surface NKG2D ligand expression has been shown to be critical for NKG2D-mediated tumor suppression in both experimental animal models and cancer patients (7, 8). In cancer patients, however, tumors evolved to escape NKG2D-mediated natural immune response by adopting a protease or exosome-mediated strategy to shed NKG2D ligands (9). As a consequence, not only tumor cells lost surface NKG2D ligands with an impaired ability to provoke an effective immune response; but more severely, the shedding-resolved soluble NKG2D ligands can sabotage the immune system via diversified mechanisms. These include down-regulating the expression and thus function of the receptor NKG2D on NK cell and effector T cells (10, 11), perturb NK cell homeostasis (7), promoting the expansion of arginase I+ myeloid-derived suppressor cells, and skewing macrophage to the tumor-promoting alternatively activated phenotypes (12). Thus, tumor-derived soluble NKG2D ligands have been broadly accepted to be highly immune suppressive and proposed as a potential cancer immune therapeutic target (13, 14).

In human, two families of NKG2D ligands, the MHC I-chain related molecules A and B (MICA/B, collectively termed MIC) and the HCMV glycoprotein UL16-binding protein family molecules (ULBPs), have been identified; among which the MIC family is most prevalently and restrictedly expressed by human cancer cells (15). Shedding of tumor cell surface MIC to release...
the soluble MIC (sMIC) into circulation is commonly found in cancer patients (16-19). Serum levels of sMIC have been well associated with progressiveness of the diseases in multiple cancer types (7, 20-23). Given the multiple immune suppressive nature of sMIC (7, 10, 12, 16), whether antibody neutralizing sMIC can revive host anti-tumor responses in MIC⁺ cancer patients is evidently an interesting therapeutic question. Due to the limitation that no MIC homolog is expressed by rodents, this critical question however remained unaddressed to date. Notably, although the signaling pathways of NKG2D are conserved across species, mouse NKG2D ligands differ from human MIC in their affinity, structure, regulation, and distribution in tumor tissues (15, 24, 25). These inherent differences preclude the translation of interesting biological conclusions discovered from mouse NKG2D ligands to human cancer.

We have recently generated a “humanized” bi-transgenic TRAMP/MIC(B) mouse model that expresses human MIC in the prostate epithelial cells of the SV40T-transgenic adenocarcinoma mouse prostate (TRAMP) directed by the prostate-specific promoter (7). The TRAMP/MIC mouse closely recapitulates the dynamic interaction of oncogenesis and NKG2D-mediated immune surveillance in human cancer patients by bridging shedding sMIC with disease progression (7). With close resemblance to MIC⁺ cancer patients (7, 17, 20, 21), high serum levels of sMIC in TRAMP/MIC mice predicted poor tumor prognosis (7). Utilizing this similarity, in this study we evaluated the therapeutic anti-tumor efficacy of a sMIC-neutralizing but non-blocking anti-MIC monoclonal antibody (mAb) B10G5 in an immune tolerant spontaneous MIC⁺ tumor model.
Materials and Methods

Animals and antibody therapy

All experimental procedures were approved by the Institutional Animal Care and Use Committee. Breeding of TRAMP/MICB has been previously described (7). Animals were randomized into two cohorts receiving therapy with \textit{i.p.} injection of sMIC-specific monoclonal antibody B10G5 or isotype control IgG (cIgG) at the dose of 4.0 mg/kg body weight twice weekly. Generation of the B10G5 antibody were described previously (7). All animals were treated for eight weeks before euthanization which was designated as the study end point. Mice received daily refreshed drinking water containing 0.8mg/mL BrdU for five consecutive days before the study endpoint. For congenic cells transfer, splenocytes were isolated from congenic CD45.1\(^+\) C57BL/6 mice (Charles River Laboratories, Frederick Cancer Research Center, Frederick, Maryland) and labeled with V\textsubscript{450} cell-trace dye according to manufacturer’s protocol (eBioscience). V\textsubscript{450}-labeled splenocytes were resuspended in PBS and injected via tail vein into recipient TRAMP/MICB mice (CD45.2\(^+\)) at the dose of 2 x 10\(^7\)/mouse five days before end point. All animals were housed in specific pathogen-free facilities. All experimental procedures were approved by the Institutional Animal Care and Use Committee. The study was repeated three times unless otherwise specified.

NK and CD8 T cell depletion

Mice were injected with antibody anti-NKp46 antibody (BioLegend) to deplete NK cells or CD8\(\alpha\)-specific antibody (clone 53-6.7, BioXcell) to deplete CD8 T cells at the dose of 200 \(\mu\text{g}/\text{mouse}\) one day before B10G5 antibody therapy and thereafter twice weekly at the dose of 100
µg/mouse till study end point. Efficiency of depletion was confirmed by flow cytometry analyses in the peripheral blood.

**Antigen-specific T cell response experiment**

CD8 T cells from TCR-I transgenic mice were labeled with CFSE and injected i.v. into animals (2x10^6 cells/mouse) that were receiving B10G5 or control IgG therapy. Animals were sacrificed at indicated time points to assess TCR-I T cell in vivo frequency with TCR-I-specific H-2D^b/Tag epitope I-tetramer (D^b/I-tetramer) (26). To assay antigen-specific CD8 T cell response, bulked splenocytes and single cell suspension of tumor-draining lymph nodes and tumor digests were stimulated overnight with 0.5 µM Tag epitope I peptide and assaying intracellular IFNγ staining of CD8^+ or D^b/I-tetramer^+ T cells.

**Tissue Collection**

Blood was collected via tail bleeding during therapy and via cardiac puncture after euthanization. Spleens and draining lymph nodes (dLN) were collected for immunological analyses. Prostate, lung, liver, kidney, pancreas, and intestines were collected, fixed in 10% neutral fixation buffer followed by paraffin embedment or directly embedded in OCT, for pathological and histological analyses. In some experiments, partial of prostate tumors was digested with collagenase for analyses of tumor infiltrated lymphocytes.

**Flow cytometry**

Single cell suspension from splenocytes, dLN, or tumor infiltrates was prepared as described (7). Combination of the following antibody was used for cell surface or intracellular staining to define populations of NK, CD8, and subsets of CD4 T cells: CD3e (clone 145-2c11),
CD8a (clone 53-6.7), CD4 (clone GK1.5), NK1.1 (clone PK136), NKG2D (clone CX5), CD45.1 (clone A20), T-bet (clone eBio4B10). For ex vivo re-stimulation, single cell suspension of freshly isolated splenocytes or LN were cultured in complete RPMI 1640 medium containing 50 ng/mL PMA and 500 ng/mL Ionomycin for 4 h and analyzed by intracellular staining with antibodies specific to IFNγ (XMG1.2). For NK cell renewal, intracellular BrdU staining was performed using anti-BrdU antibody (clone Bu20a). All antibodies and the corresponding isotype controls were fluorochrome conjugated and were purchased from eBioscience or BD Biosciences. Multi-colored Flow cytometry analyses were performed on an LSR II (BD). Data were analyzed with FlowJo software (Tree Star).

**Histology and immunohistochemistry staining (IHC)**

Prostate, Lung, and other organs were sectioned and stained with H&E for histological evaluation. For immunohistochemistry staining to detect specific antigens, the following antibodies were used: anti-SV40T (Santa Cruz), anti-Ki67 (Neomarker), anti-cleaved Caspase-3 (cell signaling, clone 5A1E), anti-CD8 (BD Biosciences), anti-NK1.1 (eBiosciences, PK136), and anti-synaptophysin (aBCAM). The IHC staining protocol has been previously described (7, 17). All tissues were counter stained with Hemotoxyline for visualization of nucleus.

**Serum sMIC, total IgG, and cytokine detection**

Serum levels of sMICB and total IgG were assessed using respective Sandwich ELISA kit (R&D systems). Serum levels of cytokines were assayed by Eve Technologies Corporation using the Luminex technology (Alberta, Canada).

**Statistical analysis**
All results are expressed as the mean ± SEM. Mouse and sample group sizes were n > 5, unless otherwise indicated. Data were analyzed using unpaired t-test, and differences were determined significant at P < 0.05. Kaplan-Meier survival curves were generated using GraphPad Prism software.

Results

Functional characterization of the anti-MIC mAb B10G5

The B10G5 mAb not only neutralizes free sMIC but also recognizes tumor cell surface membrane-bound MIC (Supplement Figure 1a and 1b), owing to sMIC sharing the same sequence and structure as the ectodomain of cell-surface MIC (16). Because B10G5 and the receptor NKG2D recognizes different epitopes of MIC (data not shown), B10G5 does not block the sensitivity of NKG2D-mediated NK cell cytolytic activity against MIC+ cells (Supplement Figure 1c). Conversely, B10G5 enhances the sensitivity of MIC+-tumor cells to NK cell cytotoxicity (Supplement Figure 1c), presumably through antibody-mediated cell cytotoxicity (ADCC) and/or enhanced immune synapse formation through simultaneously engaging NKG2D and Fc receptor on NK cells.

B10G5 antibody therapy effectively induced regression of primary tumors and eliminated metastasis

We have previously shown that TRAMP/MIC mice have greater than 40% incidence of developing highly invasive PD carcinoma and distant metastasis by 24-weeks of age (7). We also have previously determined that the accelerated tumor progression in TRAMP/MICB mice in
comparison to TRAMP littermate is associated with elevated serum sMIC and its immune suppressive effects as in cancer patients with advanced diseases (7, 20, 21, 23, 27). With the specific aim to treat advanced cancer, we treated random cohorts of 27 to 28-week old TRAMP/MIC mice with the B10G5 mAb or control mouse IgG (cIgG) twice weekly via intraperitoneal route (i.p.) at the dose of 4 mg/kg BW (body weight) (Fig. 1a). Following an eight-week therapy, all mice that received B10G5 survived whereas ~50% of mice in the control group succumbed to the disease during the same time frame with the remaining of mice showing severe symptoms of illness (Fig 1b-e and data not shown). Mice that received the 8-week B10G5 therapy had significantly smaller prostate tumor mass in comparison to those having received cIgG or to those at the same disease stage when treatment began (27-28 wk old) (Figs. 1c, d). No metastasis was found in the B10G5-treated mice. Conversely, over 90% of the mice receiving cIgG developed metastasis (Fig. 1e). Systemically, in response to B10G5 therapy, serum levels of sMIC were significantly reduced (Fig. 1f).

A remarkable serum cytokine and chemokine “storm” which was likely elicited by multitude activation of cellular immunity was evident after the 8-week B10G5 therapy (Figure 1g), as the “storm” was negatively influenced by depletion of respective specific lymphocyte subset during therapy (Supplement Figure 2). The “storm” exhibited marked elevation of major anti-tumor cytokines and immune activation chemokines, e.g. IFNγ, IL-2, IL-12, IL-9, and CCL5. No cytokine storm was elicited in TRAMP/MICB mice at any other age or tumor development stages or in non-tumor bearing TRAMP/MICB.A2 mice (7) (data not shown), suggesting that the “storm” is therapy-induced. Notably yet, no significant systemic toxicities, such as body weight loss, increase in serum IgG or C-reactive protein (CRP) or inflammation in
other organs (liver, kidney, intestinal, pancreas), were observed in response to B10G5 therapy (Figure 1h-j and data not shown).

**Therapy eliminates invasive prostate tumor cells and primes tumor microenvironment to be more immune reactive**

Histological examination revealed that animals having received B10G5 therapy exhibited a mixture of normal prostate gland and organ-defined well-differentiated prostate carcinoma, whereas mice having received cIgG therapy exhibited high frequency of invasive prostate carcinoma (Figure 2a). B10G5 therapy resulted in markedly reduced proliferation (Ki67+) and increased apoptosis (C-caspase+) of carcinoma cells (Figure 2a). In the primary tumor of majority TRAMP/MIC mice receiving cIgG or no therapy, a distinct population of disseminated tumor cells that gained neuroendocrine differentiation marker synaptophysin was abundantly present in the stroma (SYN, Figure 2a). Clinically, these tumor cell types were considered to be therapy-resistant and confer a poor prognosis (28, 29). B10G5 therapy effectively eliminated the “neuroendocrine-differentiated” tumor cells.

In most solid tumor of human cancers, tumor infiltration of NK cells correlated with better clinical outcomes or better response to therapy (30-34), suggesting an important role of NK cell in controlling cancer progression. Resembling human cancer, we have recently shown that NK cell is rarely found in poorly differentiated prostate carcinoma (7). B10G5 therapy evidently enriched NK cell infiltration in the prostate tumor parenchyma (NKp46, Figure 2b). Moreover, CD8 T cell infiltration to tumor parenchyma was also enriched by B10G5 therapy (CD8, Figure 2c).
We have recently shown that sMIC can facilitate the expansion of myeloid-derived suppressor cells (MDSC) and skew macrophage into the arginase I+ alternatively activated phenotypes (12). Consistently, TRAMP/MIC had rich infiltration of arginase I+ cells in the prostate infiltrates, which were eliminated significantly by B10G5 therapy (arginase I, Figure 2b). As arginase I can be produced by MDSC (generally defined as CD11b+Gr-1+) and/or the alternatively activated tumor-associated macrophage (generally defined as CD206+CD11c−) (35-38), we further defined these immune suppressive subsets in tumor infiltrates by flow cytometry analyses. The numbers of CD11b+Gr-1+ MDSC and CD206+CD11c− macrophages are both significantly decreases in response to B10G5 therapy (Figure 2c and 2d). Together, these data demonstrate that neutralizing sMIC primed tumor microenvironment to be more immune active.

**B10G5 therapy restores NK cell homeostasis and enhances NK and NKT cell function**

Elevated serum sMIC was shown to impair peripheral NK cell function in cancer patients at large through downregulating NKG2D expression and reducing the number of NK cells (7, 17, 18, 39). With the clinically relevant TRAMP/MIC mouse model, we demonstrated that high levels of sMIC ablates the ability of NK cells to self-renew (7). B10G5 therapy remarkably restored NK cell pool in the periphery and the ability of NK cell homeostatic to self-renew as evidenced by BrdU uptake after a consecutive 5-day BrdU pulsing (Fig. 3a-d). Moreover, B10G5 therapy markedly enhanced NK cell function, illustrated by increased production of IFNγ in response to mitogen stimulation and cytolytic ability against NKG2D ligand-positive target cells (Fig. 3e-g). Together these data conclude that targeting serum sMIC significantly restores NK cell homeostatic maintenance and function in MIC+ cancer host. The conclusion was further supported by adoptively transfer experiments with V450-labeled CD45.1 congenic NK cells to B10G5 or cIgG-treated TRAMP/MIC mice (Supplementary Figure 3). Furthermore,
although B10G5 therapy did not significantly impact the pool of NKT cells (data not shown), however, therapy enhanced Th1-like functional potential of NKT cells as represented by significantly increased IFNγ production in response to PMA/I stimulation (Fig. 3h, i).

**B10G5 therapy potentiated CD8 and CD4 T cells anti-tumor responses**

Tumor-derived sMIC has been shown to down-regulate NKG2D expression on CD8 T cells in cancer patients (16). NKG2D, as a T cell co-stimulatory receptor, is expressed by all human CD8 T cells but only by activated mouse CD8 T cells (4). B10G5 therapy in TRAMP/MIC mice significantly increased the population and number of NKG2D⁺ CD8 T cells in the periphery (Fig 4a, b), indicating activation of CD8 T cells. When stimulated ex vivo with mitogen, CD8 T cells from mice receiving B10G5 therapy had significantly higher frequency and magnitude of IFNγ production (Figs. 4c, d). Moreover, B10G5 therapy significantly increased the number of CD8 T cells with CD44^hi memory phenotype in the spleen, tumor-draining LN, and tumor infiltrates (Fig. 4e, f). Given that anergy and lack of trafficking to tumor sites are the major mechanisms of cytotoxic T dysfunction in most cancer types, these data suggest that targeting sMIC can effectively revive cytotoxic CD8 T cell anti-tumor response in cancer host.

NKG2D is rarely expressed by CD4 T cells. However, B10G5 therapy potentiated CD4 T cells to Th1 responses in the tumor draining lymph nodes, shown by the significant increases in IFNγ⁺ CD4 T cells in response to mitogenic stimulation (Fig 4g, h) and increases in T-bet expression (Supplement Figure 4). Furthermore, therapy also resulted in significant increase in CD4 T cells with CD44^hi memory phenotype (Fig 4i).
Therapy breaks CD8 T cell tumor antigenic tolerance and augments antigen-specific responses

We sought to address whether B10G5 therapy can enhance antigen-specific CD8 T cell responses. Male TRAMP mice express the SV40-T-Antigen (TAg) oncoprotein specifically in the prostate to drive spontaneous prostate tumor development through inactivation of tumor suppressor genes p53 and Rb pathways (40). Akin to the biology in cancer patients, the TAg in male TRAMP mice serves as a self-antigen and a tumor antigen, leading to tolerance of TAg and clonal deletion of TAg-specific T cells (41). Adoptively transferred naïve CD8 T cells that bear TAg-specific TCR became rapidly tolerant in TRAMP mice after initiation expansion (42).

We sought to address whether anti-sMIC antibody B10G5 therapy can enhance antigen-specific CD8 T cell responses in TRAMP/MIC mice. Because of the clonal deletion of TAg-specific CD8 T cells (41), we thus adoptively transferred CFSE-labeled naïve CD8 T cells from the TCR-I mice that express a transgenic TCR recognizing H-2D\textsuperscript{b}-restricted epitope I of the TAg (residues 206-215) (26). As examined at day 9 post-transfer, a significantly higher number of H-2D\textsuperscript{b}/epitope I-specific tetramer (D\textsuperscript{b}/I-tetramer) positive CD8 T cells was detected in the spleen, tumor-draining lymph nodes (dLN), and tumor infiltrates (TILs) of mice receiving B10G5 therapy than those receiving cIgG therapy (Figure 5a). Notably, endogenous D\textsuperscript{b}/I-tetramer\textsuperscript{+} CD8 T cells were not detectable in TRAMP/MIC mice with or without antibody treatment (Supplement Figure S5). The D\textsuperscript{b}/I-tetramer\textsuperscript{+} CD8 T cells are thus originated from adoptively transferred TCR-I cells. Consistent with findings in other studies (26, 43), adoptively transferred naïve TCR-I CD8 T cells (identified by D\textsuperscript{b}/I-tetramer\textsuperscript{+}) underwent initial rapid expansion in all mice as shown by low percentage of CFSE\textsuperscript{hi} tetramers when examined at day 9 (Figure 5b), owing to encountering TAg. However, TCR-I CD8 T cells only continued to expand in mice
receiving B10G5 therapy, as shown by marked increase in the percentage of D\textsuperscript{b}/I-tetramer\textsuperscript{+}CFSE\textsuperscript{lo} cells when examined at day 14 post-transfer (Figure 5b). We further tested antigen-specific responsiveness of CD8 T cells by stimulating single cell suspension from bulked splenocytes, tumor-draining lymph nodes, or tumor digests with TAg epitope I peptide. As shown in Figure 5c, B10G5 therapy markedly enhanced the capacity of CD8 T cells to produce IFN\(\gamma\) in response to TAg-specific epitope I peptide (TAG 206-215) stimulation.

In vitro studies have elegantly demonstrated that MIC\textsuperscript{+}-tumor cells coated with anti-MIC antibody can opsonize dendritic cells (DCs) and enhance antigen cross-presenting to CD8 T cells (44, 45). We thus further investigated whether this mechanism may contribute, at least in part, to the enhanced antigen-specific TCR-I T cells expansion and responses in the current experiment settings. As representatively shown in Figure 5d, B10G5 therapy not only enriched mature DC presence in tumor draining LN not only marked elevated the expression of DC surface activation molecule CD40 and co-stimulatory molecule CD80/86. Altogether, these data evidently demonstrated that monoclonal antibody targeting serum sMIC can effectively overcome tumor antigen-specific CD8 T cell tolerance and enhance dendritic cell priming for antigen-presentation.

Our data in the clinically relevant TRAMP/MIC mouse have demonstrated that B10G5 neutralizing sMIC can effective provoke a multitude of immune responses to suppress tumor growth and metastasis. We further substantiated these findings with experiments demonstrating that B10G5 effectively retarded the growth of transplantable TRAMP-C2 prostate tumor cell lines that express sMICB (TC2-sMICB) using the syngeneic MICB transgenic mouse model (Supplement Figures 6, 7).
As tumors can be highly heterogeneous in differentiation and surface MIC retention, we further investigated the therapeutic effect of B10G5 against tumors expressing surface MIC. We treated cohorts of TRAMP/MICB mice of 20 week-of-age, at which time most of the tumors are well-differentiated and retained surface MIC expression as we have shown (7). A significant therapeutic response was also achieved although host immune responses were amplified at discrete magnitudes (Supplement Figure 8), presumably due to dissimilar mechanisms to which conferred by neutralizing sMIC.

**Therapeutic anti-tumor effect is conferred by NK and CD8 T cells and CD4 Th1 response is NK-dependent**

To this end, our data have suggested that therapy with a monoclonal antibody B10G5 targeting sMIC effectively induces regression of advanced MIC+ malignancies through restoring innate and adaptive anti-tumor responses. We further address the contribution of NK and CD8 T cells in conferring the therapeutic effect of B10G5. Depleting NK or CD8 T cells in TRAMP/MICB mice during B10G5 therapy significantly mitigated the therapeutic effect of B10G5 (Figure 6), exemplified by a significantly higher number of animals succumbed to tumor-related death, owing to larger primary tumor burden and/or development of lung metastasis (Figure 6a-c). Depletion of CD4 T cells did not present a significant impact on therapeutic effect of B10G5 (Data not shown). Because of the functional heterogeneity of multiple CD4 T cells subsets, the outcome is somewhat anticipated.

Intriguingly, with depletion of NK cells, B10G5 therapy failed to evoke CD4 T cells to generate optimal Th1 immune responses and maintaining CD44^hi memory phenotypes (Figure 6d-f and Supplement Figure 9). Depletion of CD8 T cells had nominal effect on CD4 T cells
(data not shown). These data not only suggest that both NK and CD8 T cells are required to generate optimal anti-tumor responses, but also suggest that functional NK cells are essential for generating optimal CD4 T cell responses.

**Discussion**

Tumor-derived sMIC, whether through protease-mediated shedding or exosome secretion, has been shown to be highly immune suppressive in cancer patients through multiple mechanisms (9, 10, 46). However, whether a therapy targeting sMIC can revitalize host endogenous immune response remains untested. Using a clinically relevant double transgenic TRAMP/MIC mouse model which closely recapitulates the dynamics of serum sMIC and tumor progression, here we demonstrate that therapy with a non-blocking anti-MIC monoclonal antibody to neutralize serum sMIC effectively induce regression of advanced primary tumors and eliminated metastasis through revamping host endogenous innate and adoptive anti-tumor immune responses and remodeling tumor microenvironment. Therapy effectuated endogenous anti-tumor responses by recuperating the ability of NK cells to self-renew and to be tumor-destructive, enhancing antigen-specific CD8 T cell anti-tumor responses, and potentiating CD4 T cells to Th1 responses. Not only so, therapy also remolds tumor microenvironment demonstrated by enhancing tumor infiltration of NK cells and cytotoxic CD8 T cells and eliminating arginase I+ immune suppressive myeloid cells in tumor parenchyma. Remarkably, therapy elicited a systemic cytokine “storm” including major anti-tumor cytokines, without inducing systemic autoimmune cytotoxicity. Our study has provided the compelling first-in-field pre-clinical evidence that therapy with a sMIC-neutralizing non-blocking anti-MIC monoclonal
antibody alone can obliterate immune suppressive effective of tumor-derived sMIC and revive endogenous antitumor immune responses. Our findings define a new effective and feasible translational approach for cancer immunotherapy.

During oncogenesis, whether due to mutations in tumor suppressor genes or oncogenes, cells undergo aberrant DNA replication which initiates DNA repair responses as the cellular check point. This DNA repair response also triggers systemic checkpoint by upregulating NKG2D ligand, predominantly MIC, expression to alert the immune system to eliminate abnormal cells (1, 3). However, this onco-immunological co-evolutionary process eventually renders tumor immune escape of NKG2D-mediated immune surveillance and allows tumors to progress. Proteolytic proteases or exosome-mediated tumor-shedding of sMIC accounted for one of the major mechanisms for MIC$^+$ tumor evasion of NKG2D immune surveillance (9, 10, 46). Earlier studies demonstrated that sMIC induced global NKG2D down-modulation on all subsets of anti-tumor effector cells, such as CD8, NK, NKT, and $\gamma\delta$ T cells, in cancer patients (10, 11, 46). Recent studies have further demonstrated that sMIC can produce more profound immune suppressive effect by perturbing NK cell homeostatic maintenance and facilitating the expansion of arginase I$^+$ myeloid suppressor cells (7, 12). These studies endorsed the viability of blocking sMIC pathways in cancer immunotherapy.

How to feasibly target the immune suppressive effect of sMIC to translate into clinics is a critical question. Strategies has been proposed to blocking MIC shedding through targeting enzymes that regulates MIC shedding, such as the disulfide isomerase ERp5 (47, 48), ADAM 10/17 (49), and MMPs (50). These strategies are likely work well in early stage of diseases to retain maximal surface MIC expression and to preserve NKG2D-mediated anti-tumor immunity. In advanced cancer patients, however, providing that tumor cells lost surface MIC expression at
large as a result of shedding and that endogenous immune responses have been severely sabotaged by high serum levels of sMIC through multiple mechanisms, strategy to prevent MIC shedding is likely to elicit nominal therapeutic effect. Under this scenario, neutralizing serum sMIC with monoclonal antibody would be the logical approach in advanced cancer patients to alleviate the immune suppressive effect. Jinushi et al reported that patients who developed high titer of serum levels of anti-MIC autoantibody during clinical trial with CTLA-4 blockade and/or vaccine therapy had sustained clinical response (22, 45). These clinical findings strongly support the translational potential of our study and our unique sMIC-neutralizing non-blocking anti-MIC monoclonal antibody.

In consistent with the current understanding of the mechanisms whereby sMIC impairs host anti-tumor response, we demonstrated that our antibody neutralizing serum circulating sMIC restored NK cell homeostatic maintenance and function, restored NKG2D expression on CD8 T cells, and eliminated arginase I+ myeloid suppressor cells systemically and in tumor microenvironment. Our data suggest that the immune suppression of sMIC in cancer patients could be reversed once sMIC is removed. Beyond overcoming the multiple immune suppressive effects of sMIC, very intriguingly, B10G5 therapy also enhanced antigen-specific CD8 T cell responses and potentiated CD4 T cells to Th1 responses. More importantly, depletion of NK cells during therapy had more profound effect on CD4 T cells than on CD8 T cells. These findings suggest that the therapeutic effect on CD8 T cells is likely to be direct, whereas the effect on CD4 T cells is mediated through functional NK cells. The direct effect of anti-MIC antibody on CD8 T cell responses may in part due to enhanced DC cross-presentation of antigens on MIC+ tumor cells through opsonization (22, 44, 45). This is also supported by our data demonstrating enhanced DC activation in tumor-draining lymph nodes in response to anti-MIC
therapy. How NK may regulate the response of CD4 T cells to anti-sMIC/MIC therapy is a very interesting question and warrants for further investigation.

Our data suggest that the therapeutic effect of B10G5 is conferred by complex mechanisms through multiple pathways. These may include: 1) reducing serum circulating sMIC to alleviate the global immune suppressive effect of sMIC in advanced diseases; 2) effect of NK cell-mediated ADCC and/or enhanced immune synapse formation to enhance NKG2D-mediated interaction of NK cells with surface MIC+-tumor cells in less advanced diseases; 3) enhanced DC presentation of antigens on MIC+ tumors; 4) potential complex formation of sMIC/B10G5 and subsequent immune stimulatory effect; 5) Enhanced NK-DC cross-talk to better prime the adoptive immune responses. The impact of each mechanism on the therapeutic outcome warrants future investigation.

It is intriguing that antibody targeting sMIC therapy elicit a systemic cytokine and chemokine “storm”, but with no detectable autoimmune toxicity. Notably, therapy not only induced high serum levels of anti-tumor cytokines, such as IL-2, IFNγ, IL-9, IL-12, IL-17, but also induced cytokines that regulates immune tolerance, such as IL-4, IL-10, and IL-13. The balanced induction of immune active and immune tolerance cytokines may explain the absence of systemic autoimmune cytotoxicity. Given that MIC is a tumor-specific target, the absence of systemic autoimmunity may be reasonably expected.

In conclusion, with a “humanized’ genetic engineered mouse model that recapitulate the dynamic interaction of human NKG2D ligand MIC with tumor progression, we demonstrate that an antibody neutralizing sMIC effectively induced regression of primary tumors and eliminated metastasis in advanced MIC+ malignancy. We further demonstrated that the mechanism of tumor suppression and clearance was conferred through restoring NK cell homeostatic maintenance and
function, overcoming CD8 T cell tolerance to tumor antigen, and heightening CD4 T cells to Th1 responses, and priming DCs for enhanced antigen presentation and tumor microenvironment to be more immune reactive. Furthermore, we demonstrate a critical role of NK cells in potentiating adaptive immune responses against tumors. Collectively, our study provided the first-in-field pre-clinical evidence demonstrating that an antibody neutralizing sMIC can reset and revamp endogenous anti-tumor responses to effectuate elimination of MIC+ malignancies. Our findings are highly translatable to clinics to treat MIC+ cancers with antibodies to neutralize sMIC. Conceptually, given the global overturning of endogenous anti-tumor responses induced by the sMIC-neutralizing antibody, sMIC may be considered as a tumor-specific immune checkpoint molecule.

Disclosure of Potential Conflicts of Interest

No Potential Conflicts of Interest of all authors.

Authors’ Contributions

Conception and design: Jennifer Wu, Shengjun Lu, Zihai Li

Acquisition of data: Shengjun Lu, Jinyu Zhang, Dai Liu, Guangfu Li, Jennifer Wu

Analysis and interpretation of data: Shengjun Lu, Jinyu Zhang, Dai Liu, Kavin F Staveley-O’Carroll, Jennifer Wu

Writing and review of manuscript: Jennifer Wu, Shengjun Lu, Jinyu Zhang, Dai Liu, Guangfu Li, Kevin F Staveley-O’Carroll, Zihai Li, and Jennifer Wu

Study Supervision: Jennifer Wu
Grant Support

This work was supported by NIH-NCI grant 1R01CA149405 and A. David Mazzone - Prostate Cancer Foundation Challenge Award (to J.Wu) and in part supported by the Flow Cytometry Core Facility Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).

Figure Legends

Figure 1. sMIC-specific monoclonal antibody B10G5 is highly effective against primary prostate carcinoma and metastasis in the double transgenic TRAMP/MIC mice. (a) Depiction of treatment. TRAMP/MICB mice received 4.0 mg/kg body weight of anti-sMIC mAb B10G5 therapy or control IgG (cIgG) starting at 27 weeks old. Therapy was given twice weekly for 8 weeks. (b) Cumulative survival curve of mice receiving B10G5 therapy or control IgG. Data are combined from four independent therapy experiments. (c) Representative gross prostate size from mice receiving B10G5 therapy or cIgG at the study endpoint. (d) Summary of prostate weight (tumor) from animals receiving B10G5 therapy in comparison to those from animals receiving cIgG in parallel studies or to those from mice at the same age as therapy initiation (26-27 wk). (e) Summary of metastatic incidence. (f) B10G5 therapy reduces serum levels of sMIC measured by sandwich ELISA. (g) Levels of serum cytokines in response to therapy. Note that
the Y-axis is in log-scale. Cytokine concentration was measured by Eves Technology Inc. with cytokine multiplex assay. # indicates measure immune stimulatory cytokines. (h) Whole body weight change of mice over the treatment course. Due to large primary tumor burden, an increase in body weight was observed in animals receiving cIgG. (i) Levels of serum total IgG level at the study endpoint. (j) Levels of serum C-reactive protein (CRP) at the study endpoint.

**Figure 2.** B10G5 therapy inhibits primary tumor proliferation and survival, eliminates disseminated malignant tumor cells, and remolds prostate tumor microenvironment. a, representative micrographs demonstrating that B10G5 therapy inhibits prostate cancer cell proliferation (Ki 67+), induces tumor cell apoptosis (C-Caspase 3+), eliminates malignant disseminated neuroendocrine tumor cells from the stroma (SYN+). b, representative micrographs demonstrating that B10G5 therapy increases immune active NK (NKp46+) and CD8 T cells and decreases arginase I+ immune suppressive cells in tumor infiltrates. c, Representative flow cytometry analyses of MDSC defined by Gr-1+CD11b+ in tumor infiltrates. d, Representative flow cytometry analyses of alternatively activated macrophages defined by CD206+CD11c− in tumor infiltrates.

**Figure 3.** B10G5 therapy in TRAMP/MIC mice enhances NK cell homeostatic maintenance and function. (a, b) B10G5 therapy significantly increased the number of NK cells in the periphery. (c, d) B10G5 therapy significantly enhanced NK cell renewal as shown by the increase in the number of NK cells that are BrdU+ after five-day labeling. (e, f) B10G5 therapy significantly enhanced NK cell IFNγ production in response to PMA/ionomycin stimulation. (g) Splenic NK
cell cytotoxicity against NKG2D-L⁺ RMA-S-Rae-1 positive cells. E:T = Effector Target. (h, i) B10G5 therapy increases NKT population and functional potential shown by IFNγ production in response to PMA/I stimulation. *p<0.05; **p<0.01.

**Figure 4.** B10G5 therapy in TRAMP/MIC mice potentiates CD8 and CD4 T cell anti-tumor function. (a, b) Representative flow cytometry plots (a) and summary statistics (b) demonstrating that B10G5 therapy significantly increases the expression of the co-stimulatory NKG2D on CD8 T cells, an indication of CD8 T cell activation in mouse. (c, d) Representative flow cytometry plots (c) and summary statistics (d) demonstrating B10G5 therapy potentiates the CD8 T cell IFNγ production in response to *ex vivo* re-stimulation by PMA and ionomycin. (e, f) Representative flow cytometry CD8 T cells with CD44hi memory-phenotype. (g, h) Representative plot of flow cytometry and summary data demonstrating Th1 polarization of CD4 T cells in tumor draining LN. (i) Summary data demonstrating that B10G5 therapy increases CD44hi memory phenotype of CD4 T cells in tumor draining lymph nodes. Data are representatives of three independent studies. n > 5 for animals in each group. *p<0.05; **p<0.01.

**Figure 5.** B10G5 therapy breaks tumor antigen-specific CD8 T cell tolerance. CFSE-labeled TCR-I CD8 T cells bearing TCR specific for H-2Db-restricted TAg epitope I were adoptively transferred into cohorts of TRAMP/MICB mice (n=5-7, 2x10⁶ cells/mouse) receiving therapy with B10G5 or cIgG. Mice were euthanized at day 9 and day 14 post-transfer for analyses. Due to lack of endogenous CD8 T cells specific for TAg epitope I, adoptively transferred TCR-I specific CD8 T cells were identified by positive staining for H-2Db-TAg-epitope I tetramer
(D\(^b\)/I-tetramer). (a) Representative dot plots demonstrating frequency of D\(^b\)/I-tetramer\(^+\) CD8 T cells in the spleen, tumor-draining lymph nodes and tumor infiltrates at day 9 post-transfer. (b) Representative dot plots demonstrating proliferation of D\(^b\)/I-tetramer\(^+\) CD8 T cells at day 9 and day 14 post-transfer. (c) CD8 T cell IFN\(\gamma\) production in response to TAg epitope I stimulation. 1x10\(^6\) bulked splenocytes and single cell suspension from tumor draining lymph nodes were stimulated with 0.5 \(\mu\)M of TAg 206-215 epitope I overnight. IFN\(\gamma\) production was assessed by intracellular staining. (d) Expression of DC activation markers in tumor draining lymph nodes (day 14). Grey fill profile, mice received cIgG treatment. Black filled profile, mice received B10G5 treatment.

**Figure 6.** Impacts of NK and CD8 T cells during B10G5 therapy. Data were obtained from cohorts (n=5-8) of TRAMP/MIC mice that received *i.p.* injection with either 4 mg per kg body weight (mg kg\(^-\)) B10G5 therapy alone twice weekly or in combination with 8 mg per kg body weight (mg kg\(^-\)) anti-NKp46 antibody (Biolegend) to deplete NK cells or anti-CD8\(\alpha\) (Cedarlane Laboratories) to deplete CD8 T cells starting at the age of 27 weeks for eight consecutive weeks. All mice were sacrificed at the age of 35 weeks if not died of tumor burden. (a) A Kaplan-Meier plot showing overall survival rate. (b) Prostate weight (g) collected at sacrifice. (c) Percentage of mice with metastasis at necropsy. (d) IFN\(\gamma\) production of CD4 T cells from tumor draining lymph nodes in response to PMA/ionomycin re-stimulation. (e) T-bet expression in CD4 T cells from tumor draining lymph nodes. (f) Memory phenotype CD44\(^hi\) CD4 T cell population in tumor draining lymph nodes.
References


45. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proceedings of


Figure 1

**a**

Cancer (100%)  
WD (100%)  
PD (>40%)  
Age  6  
16  
24  
27  
35 (wks)  
TRAMP/MIC mice  
Tx (B10G5 or clgG)

**b**

Percent survival  
25  
30  
35  
age (weeks)  
Tx: control IgG (clgG)  
Tx: B10G5 mAb  
p = 0.002  
B10G5 (n=15)  
clgG (n=23)

**c**

Tx: control IgG (clgG)  
Tx: B10G5 mAb  
Mice% with Mets  
none  
0  
20  
40  
60  
80  
100  
Serum sMIC (OD450 nm)  
0.00  
0.04  
0.08  
0.12  
0.16  
0.20  
p <0.001  
p <0.01

**d**

Prostate Weight (g)  
0.0  
0.5  
1.0  
1.5  
2.0  
2.5  
clgG (35 wk)  
B10G5 (35 wk)  
No Rx (26-27 wk)  
p <0.01  
p <0.01

**e**

Mice% with Mets  
Serum sMIC (OD450 nm)  
cIgG  
B10G5  
none  
p <0.001  
p <0.01

**f**

Serum level (pg/ml)  
#  
1  
10  
100  
1000  
10000  
100000  
clgG  
B10G5  
G-CSF  
GM-CSF  
IL-1  
IL-2  
IL-4  
IL-5  
IL-6  
IL-7  
IL-9  
IL-10  
IL-12(p70)  
IL-13  
IL-17  
MCP-1  
MIP-1α  
MIP-1β  
MIP-2  
MIP-3β  
TNFα  

**g**

Serum level (pg/ml)  
clgG  
B10G5  
#  
#  
#  
#  

**h**

Body weight change (%)  
0  
5  
10  
15  
20  
25  
30  
0  
1  
2  
3  
4  
5  
6  
7  
8  
Weeks since Tx  
B10G5  
clgG  
p = 0.48  

**i**

Total serum IgG (mg/ml)  
clgG  
B10G5  
p = 0.29

**j**

serum CRP (mg/l)  
clgG  
B10G5  
p = 0.29
Figure 2

**a.** B10G5 vs. clgG

- H&E
- Ki67
- C-Caspase-3
- SYN

**b.** B10G5 vs. clgG

- NKp46
- CD8
- Arginase I

**c.** TIL, Gated on CD45^+F4/80^+

- B10G5
- clgG

Gr-1 vs. CD11b

**d.** TIL, Gated on CD45^+F4/80^+

- B10G5
- clgG

CD206 vs. CD11c

3.5 vs. 15.8

18.1 vs. 4.4
Figure 5

**a.**

- mIgG and B10G5 distributions in splenic, dLN, and TIL compartments.

**b.**

Gated on D\(^b\)/I-tetramer+ CD8 T cells:

- **Day 9:**
  - CFSE\(^lo\) clgG: 2.22, CFSE\(^lo\) B10G5: 4.69
  - CFSE\(^hi\) clgG: 6.82, CFSE\(^hi\) B10G5: 6.27
- **Day 14:**
  - CFSE\(^lo\) clgG: 2.34, CFSE\(^lo\) B10G5: 0.98
  - CFSE\(^hi\) clgG: 10.3, CFSE\(^hi\) B10G5: 0.78

**c.**

- mIgG and B10G5 distributions in IFN\(\gamma\) compartments.

**d.**

- CD11c and MHCII expression levels:
  - clgG: 0.62, B10G5: 1.77

Counts for CD40, CD80, and CD86.
Figure 6

a

Percent survival

0 10 20 30 40

0 50 100

age

B10G5
B10G5 + dpCD8
B10G5 + dpNK

* p<0.001

b

Prostate Weight (g)

0.0 1.0 2.0 3.0 4.0

clG
B10G5
B10G5 + dpNK
B10G5 + dpCD8

* *

c

mice% with lung mets

0 20 40 60 80 100

clG
B10G5
B10G5 + dpNK
B10G5 + dpCD8

* *

d

 IFN*% of CD4 (dLN)

0.0 1.0 2.0 3.0 4.0

B10G5 + mlgG
B10G5 + dpNK

**

e

T-bet*% of CD4 (dLN)

0 10 20 30 40

B10G5 + mlgG
B10G5 + dpNK

*

f

CD4*% of CD4 (dLN)

0 10 20 30

B10G5 + mlgG
B10G5 + dpNK
Non-blocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive anti-tumor responses and eliminates primary and metastatic tumors

Shengjun Lu, Jinyu Zhang, Dai Liu, et al.

Clin Cancer Res Published OnlineFirst June 23, 2015.